About us

Accumulating evidence suggests that infections and dysbiosis critically modulate the development of allergy as well as autoimmunity. The MAARS study will investigate the role of host-microbe interactions in the development and maintenance of allergy and autoimmunity using two major chronic inflammatory skin diseases, ie atopic dermatitis and psoriasis as human disease models. These two well characterized inflammatory skin diseases give us excellent possibilities to investigate pathogen driven inflammatory processes in allergies and autoimmune diseases.

For this purpose we have gathered a multidisciplinary research consortium with members that are at the forefront of biomedical research and have made significant contributions in the areas of epidemiology/risk factors of atopic dermatitis and psoriasis, genetics, innate and adaptive immune regulation, and systems biology. State-of-the-art research techniques, comprehensive patient materials and top level animal models utilizing gene-targeted mice as well as humanized mouse models are basis of our research project.

 

The Consortium

P1: THE FINNISH INSTITUTE OF OCCUPATIONAL HEALTH
Helsinki, Finland
Group leader: Dr. Harri Alenius
Coordination

P2: KAROLINSKA INSTITUTET
Huddinge, Sweden
Group leader: Dr Juha Kere, Dr Björn Andersson

P3: THE HEBREW UNIVERSITY OF JERUSALEM
Jerusalem, Israel
Group leader: Dr. Francesca Levi-Schaffer

P5: HEINRICH-HEINE-UNIVERSITAET DUESSELDORF
Düsseldorf, Germany
Group leader: Dr. Bernhard Homey

P6: INSTITUT CURIE
Paris, France
Group leader: Dr. Vassili Soumelis

P7: CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
Kiel, Germany
Group leader: Dr. Jens-Michael Schröder

P8: KING’S COLLEGE LONDON
London, United Kingdom
Group leader: Dr Frank Nestle, Dr Jonathan Barker, Dr Sophia Tsoka

P9: ICOSAGEN AS
Tartu, Estonia
Group leader: Professor Mart Ustav, CEO

P10: FIOS GENOMICS LIMITED
Edinburgh, United Kingdom
Group leader: Dr. Varrie Ogilvie

P11: HELSINGIN YLIOPISTO
Helsinki, Finland
Group leader: Dr. Annamari Ranki, Dr. Antti Lauerma

Comments are closed.